Combined assessment of EGFR-related molecules to predict outcome of 1st-line cetuximab-containing chemotherapy for metastatic colorectal cancer

References

• Galizia G, Lieto E, De Vita F, Orditura M, Castellano P, Troiani T, Imperatore V, Ciardiello F. Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer. Oncogene 2007; 26:3654-60; PMID:17530019; http://dx.doi.org/10.1038/sj.onc.1210381
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pinter T, Lim R, Bodoky G, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Eng J Med 2009; 360:1408-17; PMID:19339720; http://dx.doi.org/10.1056/NEJMoa0805019
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, Celik I, Schlichting M, Koralewski P. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011; 22:1535-46; PMID:21228335; http://dx.doi.org/10.1093/annonc/mdq632
   PubMed Web of Science ®Google Scholar
• Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:1626-34; PMID:18316791; http://dx.doi.org/10.1200/JCO.2007.14.7116
   PubMed Web of Science ®Google Scholar
• Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Eng J Med 2008; 359:1757-65; PMID:18946061; http://dx.doi.org/10.1056/NEJMoa0804385
   PubMed Web of Science ®Google Scholar
• Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, Schilsky RL. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009; 27:2091-6; PMID:19188670; http://dx.doi.org/10.1200/JCO.2009.21.9170
   PubMed Web of Science ®Google Scholar
• Dahabreh IJ, Terasawa T, Castaldi PJ, Trikalinos TA. Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Ann Intern Med 2011; 154:37-49; PMID:21200037; http://dx.doi.org/10.7326/0003-4819-154-1-201101040-00006
   PubMed Web of Science ®Google Scholar
• Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Eng J Med 2013; 369:1023-34; PMID:24024839; http://dx.doi.org/10.1056/NEJMoa1305275
   PubMed Web of Science ®Google Scholar
• Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmuller C, Kahl C, Seipelt G, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15:1065-75; PMID:25088940; http://dx.doi.org/10.1016/S1470-2045(14)70330-4
   PubMed Web of Science ®Google Scholar
• Lenz H, Niedzwiecki D, Innocenti F, Blanke C, Mahony MR, O'Neil BH, Shaw JE, Polite B, Hochster H, Atkins J, et al. 501OCALGB/SWOG 80405: PHASE III TRIAL OF IRINOTECAN/5-FU/LEUCOVORIN (FOLFIRI) OR OXALIPLATIN/5-FU/LEUCOVORIN (MFOLFOX6) WITH BEVACIZUMAB (BV) OR CETUXIMAB (CET) FOR PATIENTS (PTS) WITH EXPANDED RAS ANALYSES UNTREATED METASTATIC ADENOCARCINOMA OF THE COLON OR RECTUM (MCRC). Ann Oncol 2014; 25; PMID:25411415; http://dx.doi.org/10.1093/annonc/mdu438.13
   PubMed Web of Science ®Google Scholar
• Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, Gambacorta M, Siena S, Bardelli A. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005; 6:279-86; PMID:15863375; http://dx.doi.org/10.1016/S1470-2045(05)70102-9
   PubMed Web of Science ®Google Scholar
• Frattini M, Saletti P, Romagnani E, Martin V, Molinari F, Ghisletta M, Camponovo A, Etienne LL, Cavalli F, Mazzucchelli L. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 2007; 97:1139-45; PMID:17940504; http://dx.doi.org/10.1038/sj.bjc.6604009
   PubMed Web of Science ®Google Scholar
• Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, Wong TW, Huang X, Takimoto CH, Godwin AK, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007; 25:3230-7; PMID:17664471; http://dx.doi.org/10.1200/JCO.2006.10.5437
   PubMed Web of Science ®Google Scholar
• Saridaki Z, Tzardi M, Papadaki C, Sfakianaki M, Pega F, Kalikaki A, Tsakalaki E, Trypaki M, Messaritakis I, Stathopoulos E, et al. Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in >/= 2 line cetuximab-based therapy of colorectal cancer patients. PloS One 2011; 6:e15980; PMID:21283802; http://dx.doi.org/10.1371/journal.pone.0015980
   PubMed Web of Science ®Google Scholar
• Pentheroudakis G, Kotoula V, De Roock W, Kouvatseas G, Papakostas P, Makatsoris T, Papamichael D, Xanthakis I, Sgouros J, Televantou D, et al. Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes. BMC cancer 2013; 13:49; PMID:23374602; http://dx.doi.org/10.1186/1471-2407-13-49
   PubMed Web of Science ®Google Scholar
• Jacobs B, De Roock W, Piessevaux H, Van Oirbeek R, Biesmans B, De Schutter J, Fieuws S, Vandesompele J, Peeters M, Van Laethem JL, et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 2009; 27:5068-74; PMID:19738126; http://dx.doi.org/10.1200/JCO.2008.21.3744
   PubMed Web of Science ®Google Scholar
• Loupakis F, Cremolini C, Fioravanti A, Orlandi P, Salvatore L, Masi G, Schirripa M, Di Desidero T, Antoniotti C, Canu B, et al. EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan. Targeted Oncol 2014; 9:205-14; PMID:23821377; http://dx.doi.org/10.1007/s11523-013-0284-7
   PubMed Web of Science ®Google Scholar
• Di Fiore F, Sesboue R, Michel P, Sabourin JC, Frebourg T. Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer. Br J Cancer 2010; 103:1765-72; PMID:21139621; http://dx.doi.org/10.1038/sj.bjc.6606008
   PubMed Web of Science ®Google Scholar
• Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001; 37 Suppl 4:S3-8; PMID:11597398; http://dx.doi.org/10.1016/S0959-8049(01)00230-1
   PubMed Web of Science ®Google Scholar
• Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5:341-54; PMID:15864276; http://dx.doi.org/10.1038/nrc1609
   PubMed Web of Science ®Google Scholar
• Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 2006; 12:5268-72; PMID:17000658; http://dx.doi.org/10.1158/1078-0432.CCR-05-1554
   PubMed Web of Science ®Google Scholar
• Stintzing S, Jung A, Kapaun C, Reiche J, Modest DP, Giessen CA, Vehling-Kaiser U, Stauch M, Hass H, Fischer von Weikersthal L, et al. Ligand expression of the EGFR ligands amphiregulin, epiregulin, and amplification of the EGFR gene to predict for treatment efficacy in KRAS wild-type mCRC patients treated with cetuximab plus CAPIRI and CAPOX: Analysis of the randomized AIO CRC-0104 trial. ASCO Meeting Abstracts 2012; 30:3519.
   Google Scholar
• Seligmann JF, Elliott F, Richman SD, Jacobs B, Hemmings G, Brown S, Barrett JH, Tejpar S, Quirke P, Seymour MT. Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer. JAMA Oncol 2016; PMID:26867820; http://dx.doi.org/10.1001/jamaoncol.2015.6065
   PubMedGoogle Scholar
• Stahler A, Heinemann V, Giessen-Jung C, Crispin A, Schalhorn A, Stintzing S, Fischer von Weikersthal L, Vehling-Kaiser U, Stauch M, Quietzsch D, et al. Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial). Int J Cancer 2016; 138:739-46; PMID:26284333; http://dx.doi.org/10.1002/ijc.29807
   PubMed Web of Science ®Google Scholar
• Yang JL, Qu XJ, Russell PJ, Goldstein D. Regulation of epidermal growth factor receptor in human colon cancer cell lines by interferon alpha. Gut 2004; 53:123-9; PMID:14684586; http://dx.doi.org/10.1136/gut.53.1.123
   PubMed Web of Science ®Google Scholar
• Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzman M, Rodriguez S, Arribas J, Palacios J, et al. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin Cancer Res 2004; 10:6487-501; PMID:15475436; http://dx.doi.org/10.1158/1078-0432.CCR-04-0870
   PubMed Web of Science ®Google Scholar
• Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009; 27:5924-30; PMID:19884556; http://dx.doi.org/10.1200/JCO.2008.21.6796
   PubMed Web of Science ®Google Scholar
• Sartore-Bianchi A, Moroni M, Veronese S, Carnaghi C, Bajetta E, Luppi G, Sobrero A, Barone C, Cascinu S, Colucci G, et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 2007; 25:3238-45; PMID:17664472; http://dx.doi.org/10.1200/JCO.2007.11.5956
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Finocchiaro G, Rossi E, Janne PA, Carnaghi C, Calandri C, Bencardino K, Ligorio C, Ciardiello F, Pressiani T, et al. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol 2008; 19:717-23; PMID:17974556; http://dx.doi.org/10.1093/annonc/mdm492
   PubMed Web of Science ®Google Scholar
• Scartozzi M, Bearzi I, Mandolesi A, Pierantoni C, Loupakis F, Zaniboni A, Negri F, Quadri A, Zorzi F, Galizia E, et al. Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis. BMC Cancer 2009; 9:303; PMID:19712476; http://dx.doi.org/10.1186/1471-2407-9-303
   PubMed Web of Science ®Google Scholar
• Personeni N, Fieuws S, Piessevaux H, De Hertogh G, De Schutter J, Biesmans B, De Roock W, Capoen A, Debiec-Rychter M, Van Laethem JL, et al. Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study. Clinical Cancer Res 2008; 14:5869-76; PMID:18794099; http://dx.doi.org/10.1158/1078-0432.CCR-08-0449
   PubMed Web of Science ®Google Scholar
• Perrone F, Lampis A, Orsenigo M, Di Bartolomeo M, Gevorgyan A, Losa M, Frattini M, Riva C, Andreola S, Bajetta E, et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 2009; 20:84-90; PMID:18669866; http://dx.doi.org/10.1093/annonc/mdn541
   PubMed Web of Science ®Google Scholar
• Razis E, Briasoulis E, Vrettou E, Skarlos DV, Papamichael D, Kostopoulos I, Samantas E, Xanthakis I, Bobos M, Galanidi E, et al. Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study. BMC cancer 2008; 8:234; PMID:18700047; http://dx.doi.org/10.1186/1471-2407-8-234
   PubMed Web of Science ®Google Scholar
• Stintzing S, Kapaun C, Laubender RP, Jung A, Neumann J, Modest DP, Giessen C, Moosmann N, Wollenberg A, Kirchner T, et al. Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group. Int J Cancer 2013; 132:236-45; PMID:22644776; http://dx.doi.org/10.1002/ijc.27654
   PubMed Web of Science ®Google Scholar
• Miyazaki M, Furuya T, Shiraki A, Sato T, Oga A, Sasaki K. The relationship of DNA ploidy to chromosomal instability in primary human colorectal cancers. Cancer Res 1999; 59:5283-5; PMID:10537310
   PubMed Web of Science ®Google Scholar
• Ooi A, Takehana T, Li X, Suzuki S, Kunitomo K, Iino H, Fujii H, Takeda Y, Dobashi Y. Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. Mod Pathol 2004; 17:895-904; PMID:15143334; http://dx.doi.org/10.1038/modpathol.3800137
   PubMed Web of Science ®Google Scholar
• Graziano F, Ruzzo A, Loupakis F, Canestrari E, Santini D, Catalano V, Bisonni R, Torresi U, Floriani I, Schiavon G, et al. Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. J Clin Oncol 2008; 26:1427-34; PMID:18349392; http://dx.doi.org/10.1200/JCO.2007.12.4602
   PubMed Web of Science ®Google Scholar
• Pander J, Gelderblom H, Antonini NF, Tol J, van Krieken JH, van der Straaten T, Punt CJ, Guchelaar HJ. Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer. Eur J Cancer 2010; 46:1829-34; PMID:20418097; http://dx.doi.org/10.1016/j.ejca.2010.03.017
   PubMed Web of Science ®Google Scholar
• Lurje G, Nagashima F, Zhang W, Yang D, Chang HM, Gordon MA, El-Khoueiry A, Husain H, Wilson PM, Ladner RD, et al. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab. Clin Cancer Res 2008; 14:7884-95; PMID:19047118; http://dx.doi.org/10.1158/1078-0432.CCR-07-5165
   PubMed Web of Science ®Google Scholar
• Park JH, Han SW, Oh DY, Im SA, Jeong SY, Park KJ, Kim TY, Bang YJ, Park JG. Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer. Cancer Chemother Pharmacol 2011; 68:1045-55; PMID:21340604; http://dx.doi.org/10.1007/s00280-011-1586-z
   PubMed Web of Science ®Google Scholar
• Dahan L, Norguet E, Etienne-Grimaldi MC, Formento JL, Gasmi M, Nanni I, Gaudart J, Garcia S, Ouafik L, Seitz JF, et al. Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer. BMC Cancer 2011; 11:496; PMID:22117530; http://dx.doi.org/10.1186/1471-2407-11-496
   PubMed Web of Science ®Google Scholar
• Liu W, Innocenti F, Chen P, Das S, Cook EH, Jr., Ratain MJ. Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. Clin Cancer Res 2003; 9:1009-12; PMID:12631599
   PubMed Web of Science ®Google Scholar
• Tol J, Dijkstra JR, Klomp M, Teerenstra S, Dommerholt M, Vink-Borger ME, van Cleef PH, van Krieken JH, Punt CJ, Nagtegaal ID. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur J Cancer 2010; 46:1997-2009; PMID:20413299; http://dx.doi.org/10.1016/j.ejca.2010.03.036
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Lenz HJ, Kohne CH, Heinemann V, Tejpar S, Melezinek I, Beier F, Stroh C, Rougier P, van Krieken JH, et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol 2015; 33:692-700; PMID:25605843; http://dx.doi.org/10.1200/JCO.2014.59.4812
   PubMed Web of Science ®Google Scholar
• De Vriendt V, De Roock W, Di Narzo AF, Tian S, Biesmans B, Jacobs B, Budinska E, Sagaert X, Rossi S, D'Ario G, et al. DUSP 4 expression identifies a subset of colorectal cancer tumors that differ in MAPK activation, regardless of the genotype. Biomarkers 2013; 18:516-24; PMID:23875912; http://dx.doi.org/10.3109/1354750X.2013.819038
   PubMed Web of Science ®Google Scholar
• Oliveras-Ferraros C, Vazquez-Martin A, Cufi S, Queralt B, Baez L, Guardeno R, Hernandez-Yague X, Martin-Castillo B, Brunet J, Menendez JA. Stem cell property epithelial-to-mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbitux) efficacy in KRAS wild-type tumor cells. J Cell Biochem 2011; 112:10-29; PMID:21104905; http://dx.doi.org/10.1002/jcb.22952
   PubMed Web of Science ®Google Scholar
• Amador ML, Oppenheimer D, Perea S, Maitra A, Cusatis G, Iacobuzio-Donahue C, Baker SD, Ashfaq R, Takimoto C, Forastiere A, et al. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res 2004; 64:9139-43; PMID:15604284; http://dx.doi.org/10.1158/0008-5472.CAN-04-1036
   PubMed Web of Science ®Google Scholar
• Miller R, Siegmund D. Maximally selected chi square statistics. Biometrics 1982; 38:1011-16; http://dx.doi.org/10.2307/2529881
   Web of Science ®Google Scholar
• Halpern J. Maximally selected chi square statistics for small samples. Biometrics 1982; 38:1017-23; http://dx.doi.org/10.2307/2529882
   Web of Science ®Google Scholar
• Vallbohmer D, Zhang W, Gordon M, Yang DY, Yun J, Press OA, Rhodes KE, Sherrod AE, Iqbal S, Danenberg KD, et al. Molecular determinants of cetuximab efficacy. J Clin Oncol 2005; 23:3536-44; PMID:15908664; http://dx.doi.org/10.1200/JCO.2005.09.100
   PubMed Web of Science ®Google Scholar